DUBLIN, Ohio, November 28, 2018 — Cordis, a Cardinal Health company (NYSE: CAH), today announced that the U.S. Food and Drug Administration (FDA) has approved its INCRAFT® AAA Stent Graft System for use in complex access anatomies. The INCRAFT system is an ultra-low profile and flexible endovascular aneurysm repair (EVAR) system designed […]
Other News
Lexington Announces Q3 2018 Financial Results and Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 29, 2018 (GLOBE NEWSWIRE) — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces the release of the Company’s Condensed Consolidated Interim Financial Statements and the Management’s Discussion and Analysis for the three and nine month period ended September 30, 2018 and 2017 which are […]
Micro Interventional Devices, Inc.™ Announces Continued Successful Enrollment in STTAR Trial
NEWTOWN, Pa., Nov. 29, 2018 /PRNewswire/ — Micro Interventional Devices, Inc.™ (MID) announced the continued successful enrollment of patients in STTAR (the Study of Transcatheter Tricuspid Annular Repair) being conducted in Europe. MID’s MIA™, Minimally Invasive Annuloplasty technology, is being studied for its safety and performance in the treatment of severe tricuspid regurgitation. MIA […]
Millar Announces Discontinuation of CD Leycom Distribution Agreement
HOUSTON, Nov. 29, 2018 /PRNewswire/ — Millar, Inc., medical device manufacturer and OEM innovation partner, announced today that the company will end its distribution agreement with CD Leycom, manufacturer of the clinical Inca® Pressure-Volume (PV) Loop System, on December 31, 2018. Millar has been the exclusive distributor within North America for CD Leycom since November 2013. The CD Leycom Inca […]
MERIT MEDICAL RECEIVES 510(K) APPROVAL FOR EMBOCUBE EMBOLIZATION GELATIN FOR EMBOLIZATION OF HYPERVASCULAR TUMORS
SOUTH JORDAN, Utah – November 29, 2018 – Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in interventional, diagnostic and therapeutic procedures, announces that it has received 510(k) clearance for EmboCube Embolization Gelatin. EmboCube is indicated for use in embolization of hypervascular tumors. The […]
Reprieve Cardiovascular introduces guided diuretic therapy at major heart failure congresses
MILFORD, Massachusetts – ( BUSINESS WIRE ) – Reprieve Cardiovascular ™, a pioneering medical device company focused on improving the treatment of patients with acute decompensated heart failure (ADHF), will soon be at various well-known sites Conferences for Heart Failure represented. Reprieve-guided diuretic therapy will be the subject of the two presentations […]
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 28, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s president and chief executive officer, is scheduled to participate in a fireside chat regarding […]
InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details from several presentations of updated CGuard™ EPS data at the recent VEITHsymposium […]
First Patient Treated In Biosense Webster U.S. IDE Study Evaluating Next Generation Balloon Ablation Catheter For Atrial Fibrillation
IRVINE, Calif., Nov. 29, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its STELLAR** U.S. Investigational Device Exemption (IDE) study. The study will evaluate the safety […]
CardioFocus Completes Enrollment In HeartLight® X3 Trial
MARLBOROUGH, Mass., Nov. 29, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced completed enrollment in a trial to evaluate its next-generation HeartLight® X3 Endoscopic Ablation System. A total of 60 patients have been treated in this pivotal confirmatory trial with a one-month […]



